Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 24

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 24
---
 to invest in our securities.                       |
| Dividend policy |     | We have never declared or paid any cash dividends to our shareholders, and we currently do not expect to declare or pay any cash dividends in the foreseeable future. See “Dividend Policy.” |
| Listing         |     | Our Depositary Shares are listed on the NASDAQ Capital Market under the symbol “BDRX.”                                                                                                       |

| 12 |

<div align='center'>RISK FACTORS</div>

Our business has significant risks. In addition to the other information included in this annual report, including the matters addressed in the section of the annual report entitled “Cautionary Note Regarding Forward-Looking Statements” and in our financial statements and the related notes, you should consider carefully the risks described below. The risks and uncertainties described below are not the only risks and uncertainties we may face. Additional risks and uncertainties not presently known to us, or that we currently consider immaterial could also negatively affect our business, financial condition, results of operations, prospects, profits and stock prices. If any of the risks described below actually occur, our business, financial condition, results of operations, prospects, profits and stock prices could be materially adversely affected.

Summary of Risk Factors

The occurrence of one or more of the events or circumstances described in this section titled “ Risk Factors,” alone or in combination with other events or circumstances, may materially adversely affect our business, financial condition and operating results. In that event, the trading price of our securities could decline, and you could lose all or part of your investment. Such risks include, but are not limited to:

| • | It is not possible to predict the actual number of Depositary Shares, if any, we will sell under the Purchase 
 Agreement, or the actual gross proceeds resulting from those sales or the dilution to you from those sales.   |

| • | Future resales and/or issuances of our Depositary Shares, including pursuant to this prospectus, or the 
 perception that such sales may occur, may cause the market price of our shares to drop significantly.   |

| • | We have incurred significant losses since our inception and anticipate that we will continue to incur 
 losses in the future.                                                                                 |

| • | Our requirement for additional financing in the short-term represents a material uncertainty that raises 
 substantial doubt about our ability to continue as a going concern.                                      |

| • | If we require or seek to raise additional capital to fund our operations and we fail to obtain necessary 
 financing, we may